Suven Life Sciences Ltd has been granted one product patent from India (289123) and one product patent from the United States of America (9790211) corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2029 and 2033 respectively.

The granted claims of the patents include the class of selective Alpha4 Beta2 and 5-HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson, and Schizophrenia respectively.


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version